🇪🇺 BNT162b2 (2025/2026 formulation) in European Union

BNT162b2 (2025/2026 formulation) (bnt162b2-2025-2026-formulation) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

BNT162b2 (2025/2026 formulation) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is BNT162b2 (2025/2026 formulation) approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for BNT162b2 (2025/2026 formulation) in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.